Lapierre Yvon D
Journal of Psychiatry & Neuroscience.
J Psychiatry Neurosci. 2003 Sep;28(5):340-7.
The red flags raised by the 1990 clinical reports of increased suicidality associated with treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine were followed by anecdotal reports of similar symptoms with other antidepressants of the same class. Recent discussions by Healy have argued in favour of a suicidogenic potential of the SSRIs. This paper reviews the relevant literature addressing the epidemiological data of Western populations and the data accumulated from clinical trial databases in several countries. The evidence currently available does not support the hypothesis that antidepressants or, more specifically, SSRIs cause increased suicidality in patients with depression, nor do they appear to do so in patients treated with these drugs for other reasons.
1990年的临床报告指出,选择性5-羟色胺再摄取抑制剂(SSRI)氟西汀治疗会增加自杀倾向,这引发了警示信号,随后有轶事报道称,同一类别的其他抗抑郁药也有类似症状。希利最近的讨论支持了SSRI具有潜在自杀诱导作用的观点。本文回顾了相关文献,涉及西方人群的流行病学数据以及几个国家临床试验数据库积累的数据。目前可得的证据并不支持抗抑郁药,更具体地说是SSRI会导致抑郁症患者自杀倾向增加这一假说,而且在因其他原因使用这些药物治疗的患者中似乎也并非如此。